Spots Global Cancer Trial Database for philadelphia chromosome positive acute lymphoblastic leukemia
Every month we try and update this database with for philadelphia chromosome positive acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00101595 | Chronic Myeloid... Leukemia, Lymph... | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation | ||
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | NCT00109707 | Chronic Myeloge... Acute Lymphobla... Hypereosinophil... Systemic Mastoc... | Nilotinib | 18 Years - | Novartis | |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects | NCT00529763 | Leukemia | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00101595 | Chronic Myeloid... Leukemia, Lymph... | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL | NCT05594784 | Philadelphia Ch... | Olverembatinib Venetoclax prednisone Vincristine | 14 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Rollover Study of BMS-354825 in Patients With CML and Ph+ALL | NCT01030718 | Chronic Myeloge... Philadelphia Ch... | dasatinib | 20 Years - 75 Years | Bristol-Myers Squibb | |
| Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects | NCT00529763 | Leukemia | Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
